ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia Post author:admERY Post published:September 30, 2014 Post category:Newsroom ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia. You Might Also Like ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL April 20, 2021 ERYTECH to Present at the 2021 BIO CEO & Investor Conference February 10, 2021 ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference May 30, 2018
